Sermorelin vs ipamorelin

At a glance

Evidence grade

Where a compliant provider sells this today

The short answer

Sermorelin and ipamorelin are not two strengths of one product. They are two different molecules that push on two different receptors, both of which end at the same place: growth hormone leaving the pituitary gland.

That difference is real pharmacology and it is the honest part of the marketing. What follows it is not. Neither compound has been tested in controlled human trials against the outcomes adults are actually buying, and the receptor each one uses does not change that.

This page compares what is known about each. It gives no dosing, no route and no recommendation, because the question of whether either belongs in a given person’s care belongs to a prescriber who knows their history.

Two doors into the same room

The pituitary responds to two separate signals. Growth-hormone-releasing hormone is the body’s main accelerator for the system, and it works through its own receptor. Ghrelin works through a different one. Ghrelin does two things at once: it amplifies release, and it suppresses the braking signal that normally holds release down.

Sermorelin is built from the first signal. It is the shortest piece of growth-hormone-releasing hormone that still carries the activity of the whole molecule. Ipamorelin acts on the second receptor, the one ghrelin binds.

This is why the two show up next to each other on clinic menus, and why they are so often sold in the same vial. Two inputs feed one output. The rationale is genuine. A rationale is not a result.

What each one has actually been shown to do

Sermorelin provokes a growth hormone response. That is not a contested claim. It is the property an approved diagnostic product was built on, and a test that asks whether a pituitary gland can respond only works if the agent reliably makes a working gland respond.

Ipamorelin’s documented contribution is selectivity. The earlier compounds acting on its receptor also nudged other pituitary hormones, notably cortisol and prolactin. Ipamorelin’s original pharmacology described it as releasing growth hormone with far less of that spillover. That is a real reported finding, not a marketing invention.

Read both of those carefully. One is a statement about whether a gland responds. The other is a statement about which hormones move. Neither is a statement about what happens to a person over months.

The gap is the same gap on both sides

The uses these compounds are marketed for are outcomes: body composition, sleep quality, recovery, joint comfort, energy, and the general promise of slowing how aging feels.

Establishing any of that takes trials in the population being sold the product, run against a placebo. They have to run long enough for a durable effect to separate from a temporary one. They have to measure the thing a person would notice rather than a number a lab reports. That body of work does not exist for either compound.

What exists instead is a large volume of clinic testimonial and before-and-after reporting with no control group in it. Neither of these compounds is better off than the other on that count. If a page tells you one is the evidence-backed choice, ask which trial it is pointing at.

Where the histories genuinely diverge

Sermorelin has a regulatory past. It was approved and sold in the United States under the brand name Geref, as a diagnostic agent, and in a separate presentation for growth failure in children with growth hormone deficiency. The manufacturer discontinued it. Everything sold here now is compounded.

Ipamorelin has no such history. It was carried into clinical development and did not reach approval, and it has never been marketed in the United States as an approved product.

That is a difference in paper trail, not a difference in adult outcome evidence. Sermorelin’s approvals answered questions about pituitary testing and about children with a deficiency. They say nothing about a healthy forty-five-year-old, and no one should let the word "approved" travel further than the indication it was attached to.

Where the regulatory question sits

Sermorelin is not currently marketed in the United States as an FDA-approved product, so what is sold here is compounded. Ipamorelin holds no FDA approval either. The rules governing which substances may be compounded are contested rather than settled, and no outcome is characterized here.

Regulatory positions move, and a summary written into a comparison drifts out of date the moment the record changes. Each compound’s status page carries the dated record, and that is where the current position is stated.

One thing can be said plainly regardless. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, whatever an individual pharmacy’s own standards are. That describes the review pathway. It is not an accusation about any pharmacy.

How the grades were set

Both compounds are graded limited evidence, and the grade means the same thing in both places. Each has a defined receptor target and a documented, reproducible effect on hormone release in people. That puts them above compounds whose entire case rests on cell culture and animal work.

Neither has controlled outcome data for the uses it is actually sold for, which keeps both well short of strong. The grade is not an endorsement and it is not a warning. It is a description of how much has been measured.

If randomized placebo-controlled trials in adults appear for either one, the grade moves for that one. Until then, a buyer choosing between them is choosing between two compounds with the same shape of missing evidence.